Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDUA | P35475 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FGF2 | P09038 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 2/20 | 0.32 |
| ▸ | SELL | P14151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13969565 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL13377847 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL8340283 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL19848245 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL15473351 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL23502390 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL13887430 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL17906334 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL20800901 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL749480 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424956-A1 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | Genzyme Corporation (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20130156788-A1 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 | OXFORD BIOTHERAPEUTICS LTD (GB) | 2013-06-20 | — | — | US | disclosed |
| US-8420084-B2 | Fully human antibodies specific to CADM1 | MEDAREX, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120027782-A1 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110085970-A1 | ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-14 | — | — | US | disclosed |
| US-20110020329-A1 | CONJUGATES OF ANTI-RG-1 ANTIBODIES | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| US-7655646-B2 | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals | THALLION PHARMACEUTICALS, INC. (CA) | 2010-02-02 | — | — | US | disclosed |
| US-7655646-B2 | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals | THALLION PHARMACEUTICALS, INC. (CA) | 2010-02-02 | — | — | US | disclosed |
| US-20090162372-A1 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE | MEDAREX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080161291-A1 | DIBENZODIAZEPINONE ANALOGUES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | THALLION PHARMACEUTICALS INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161291-A1 | DIBENZODIAZEPINONE ANALOGUES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | THALLION PHARMACEUTICALS INC. | 2008-07-03 | — | — | US | disclosed |
| US-7304054-B2 | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals | THALLION PHARMACEUTICALS INC. (CA) | 2007-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162372-A1 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE | FN1, EDNRB, EDF1 | IDUA 299/4885SUCNR1 4395/4885CA9 3439/4885 |
| US-20110085970-A1 | ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE | CD2BP2, CD274, CD22 | IDUA 3247/4885SUCNR1 3943/4885CA9 2355/4885 |
| US-20080161291-A1 | DIBENZODIAZEPINONE ANALOGUES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | UGT2B17, CYP1B1, CYP2C19 | IDUA 334/4885SUCNR1 2377/4885CA9 2247/4885 |
| US-20130156788-A1 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 | FCGR1A, FCGR2A, FCGR3B | IDUA 1550/4885SUCNR1 3198/4885CA9 1300/4885 |
| US-20110020329-A1 | CONJUGATES OF ANTI-RG-1 ANTIBODIES | GDI1, ARFGAP1, GLG1 | IDUA 1887/4885SUCNR1 2023/4885CA9 3430/4885 |
| US-20120027782-A1 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) | PTK2, PTK2B, LTK | IDUA 4457/4885SUCNR1 4255/4885CA9 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.